Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2025 09:00 ET | Source: BioBridge Global

BBG Advanced Therapies collects first cell donation on one-of-a-kind bus

San Antonio, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global...
October 08, 2025 03:00 ET | Source: BioBridge Global

BBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)

San Antonio, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- BBG Advanced Therapies, a subsidiary of BioBridge Global (San Antonio, Texas, USA), and CELLforCURE, part of SEQENS Group, (Les Ulis, France)...
October 07, 2025 08:26 ET | Source: BioBridge Global

BBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)

San Antonio, Texas, Oct. 07, 2025 (GLOBE NEWSWIRE) -- BBG Advanced Therapies, a subsidiary of BioBridge Global (San Antonio, Texas, USA), and CELLforCURE, part of SEQENS Group, (Les Ulis, France)...
October 06, 2025 07:05 ET | Source: 4Bio Capital

4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells...
October 06, 2025 02:05 ET | Source: 4Bio Capital

4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells...
September 24, 2025 10:07 ET | Source: Pluristyx, Inc.

Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions

Pluristyx and Solesis partner to launch game-changing standardized organoid kits, powered by iPSC and polymer technologies.
September 04, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies

Pluristyx & BioLamina partner to accelerate iPSC-based therapies with integrated cell culture solutions, for consistency, scalability & clinical success.
July 31, 2025 09:00 ET | Source: Alira Health

The Global Biologics Outsourcing Market Accounted for $20.7B in 2024 Driven by Rising Demand for Modality-Specific, End-to-End CDMO Capabilities, Finds Alira Health

This Alira Health report offers analysis of the global rebound in biologics outsourcing following a year of macroeconomic headwinds and market contraction.
July 09, 2025 08:00 ET | Source: 4Bio Capital

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean...
July 09, 2025 03:00 ET | Source: 4Bio Capital

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean...